COLL Q2: ADHD Growth Is Real, but Pain Headwinds Made Investors Shrug

Investors Focused on the Revenue Miss and Lower-Than-Expected Profit Guidance

COLL fell 13.5% in premarket trading after reporting $199.9 million in Q2 revenue, slightly below expectations. At the same time, non-GAAP EPS of $1.92 beat consensus, and management raised full-year revenue guidance to $840 million from $815 million. The mixed reaction makes sense: the quarter was profitable, but operating margin fell to 1.9% from 18.7%, and full-year EBITDA guidance landed below analyst estimates.

The market was not rejecting the ADHD story. It was signaling that better earnings alone were not enough while the legacy pain business continued to weaken and set a lower run rate for the year.

JORNAY PM and Azstarys Show Real ADHD Demand

The core question after the print was whether Collegium's ADHD growth reflected genuine demand or only short-term accounting optics. On that score, the quarter looked constructive.

JORNAY PM demand is broadening

Prescriptions grew 13.1%. Net revenue reached $46.1 million, and prescribers hit an all-time high of more than 30,000. Management also said awareness, physician favorability, and intent to prescribe have all improved meaningfully. Taken together, those signals point to continued demand rather than a purely financial display.

Azstarys is becoming part of the franchise

Collegium closed the Azstarys acquisition in May, said integration is complete, and reported AZSTARYS Revenue: $12.9 million, reflecting about a month and a half of commercial sales. That is only a debut, not proof of long-term scale, but it does show the ADHD pipeline is becoming a two-product franchise instead of a one-brand fix.

The sales setup now supports execution

the company has expanded its ADHD sales force to about 190 reps and its target physician universe to about 27,000. Reps are now selling both JORNAY PM and AZSTARYS across the full target base, which gives the second half a clearer path to compounding rather than relying on a single seasonal spike.

The main near-term catalyst is the back-to-school season. Management expects it to support continued momentum, but investors will want to see that momentum translate into sustained revenue rather than just optimistic commentary.

Pain Business Cash Flow Is Still Important, but the Decline Is Harder to Ignore

BELBUCA Is Holding Up Better Than the Rest of the Pain Portfolio

BELBUCA is still helping fund the transition, with Belbuca net revenue of $57.7 million, up 10% year over year. XTAMPZA ER is slipping, down to $45 million and down 14% year over year. The bigger pressure point is the NUCYNTA franchise, which produced $35.2 million, down 24% year over year, including $5.1 million from profit share on authorized generics.

That mix matters. The pain business is not just softer; some of the pressure is coming from authorized-generic pricing, which can be a more persistent drag than a temporary demand dip.

Guidance Shows the Revenue Pressure Is Carrying Into the Full Year

The company lifted its revenue guidance for the full year to $840 million at the midpoint from $815 million, but that remained below consensus. EBITDA guidance for the full year is $457.5 million at the midpoint, below analyst estimates of $482.8 million.

That is the real reason investors reacted negatively despite the EPS beat. The legacy pain business is still producing cash, but it is no longer providing the same amount of cushion for the company's transition.

The Balance Sheet Buys Time, Not Certainty

Collegium generated Operating Cash Flow: $71.3 million in Q2 2026 and ended the quarter with Cash and Marketable Securities: $129.5 million. That gives management time to support the ADHD push while the pain portfolio adjusts. The key risk is timing: if NUCYNTA keeps weakening faster than ADHD can replace it, the handoff will look slower than investors wanted.

What Would Restore Investor Confidence in COLL?

The transition story itself is no longer the issue. Jornay PM prescriptions grew 13.1%, Azstarys integration is complete, and management sees continued momentum through the back-to-school season.

What matters now is whether ADHD growth keeps strengthening while the pain decline stabilizes. The main watch points are straightforward:

• JORNAY PM needs to keep broadening beyond over 30,000 prescribers and convert improved intent into consistent prescribing.
• Azstarys needs to build on its partial-quarter start and become a more meaningful contributor in the second half.
• The pain portfolio needs to stop setting lower expectations for full-year revenue and EBITDA.

If those pieces line up, the stock can start to reflect the ADHD story more cleanly. If not, Collegium will remain in prove-it mode.